CRC Research Update — September 22, 2026
Today's colorectal cancer research highlights
Alex Chompff
Nutritional and inflammatory markers may predict outcomes in metastatic CRC
Skip to content
The CRC Digest
Nutritional and inflammatory markers may predict outcomes in metastatic CRC
A supplementary analysis of the JCOG1007 trial examined whether pretreatment modified Glasgow Prognostic Score, albumin, and C-reactive protein were associated with differential outcomes after upfront primary tumor resection. (Ann Surg Oncol)
This content is
Quality of life in CRC patients linked to their caregivers' well-being
Skip to content
The CRC Digest
Quality of life in CRC patients linked to their caregivers' well-being
A multicenter study of 119 patient-caregiver dyads found an association between patients' and caregivers' health-related quality of life scores. (Adv Ther)
This content is informational only and does not constitute
Experts call for personalized screening based on individual risk factors beyond family history
Skip to content
The CRC Digest
▪ SCREENING
Experts call for personalized screening based on individual risk factors beyond family history
A review in Expert Review of Gastroenterology & Hepatology notes that while overall CRC incidence has declined, younger patients have experienced a rise, suggesting a more complex risk profile than
MSS colorectal cancer may not be universally immunotherapy-resistant
Skip to content
The CRC Digest
◇ RESEARCH
MSS colorectal cancer may not be universally immunotherapy-resistant
A review in Trends in Cancer argues that resistance in proficient mismatch repair tumors is conditional, shaped by disease stage, metastatic anatomy, and spatial immune architecture rather than being uniformly "cold." (Trends Cancer)
Gut bacterium Eggerthella lenta linked to liver metastasis via vascular barrier disruption
Skip to content
The CRC Digest
◇ RESEARCH
Gut bacterium Eggerthella lenta linked to liver metastasis via vascular barrier disruption
Multi-omics analysis of two cohorts comprising 20 healthy controls, 82 non-metastatic CRC patients, and 65 patients with liver or lung metastases found that those with CRC liver metastasis had impaired gut
Fruquintinib approved in U.S., EU, and China for previously treated metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Fruquintinib approved in U.S., EU, and China for previously treated metastatic CRC
This oral VEGF receptor inhibitor demonstrated consistent efficacy in two Phase 3 trials: FRESCO (enrolling patients in China) and FRESCO-2 (enrolling patients across 14 countries in North America, Europe, Asia,
CRC Research Update — September 21, 2026
Today's colorectal cancer research highlights
Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases
Skip to content
The CRC Digest
◇ RESEARCH
Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases
A comprehensive review reports that hereditary cancer syndromes account for 20-25% of early-onset colorectal cancer cases, with most occurring in the absence of known genetic predispositions. (Oncology Therapy)
This content is informational only and
Mobile Health Intervention Increases CRC Awareness in Young Black Men
Skip to content
The CRC Digest
▪ SCREENING
Mobile Health Intervention Increases CRC Awareness in Young Black Men
A 14-day pilot mHealth intervention called PRISM showed preliminary evidence of increasing colorectal cancer knowledge among 20 Black men aged 18-25 in Virginia. (Ethnicity & Health)
This content is informational only and does